At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
20 mg MitoQ +2 moredrug
Likely dose
20 mg MitoQfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial
In Brief
A Phase 2 clinical trial evaluating 20 mg MitoQ, Placebo, and 1 other intervention for Multiple Sclerosis and Fatigue. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Fatigue
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartApr 2020
Primary CompletionOct 2024
Study CompletionMar 2026
TodayJul 2026
First PostedFeb 13, 2020
Enrollment StartApr 1, 2020
Primary CompletionOct 15, 2024
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 6.4 years ago
Interventions
20 mg MitoQdrug
a third of subject will receive 20mg of oral MitoQ
Placebodrug
Subject will receive Placebo
40mg of MitoQdrug
a third of subjects will receive 40mg of MitoQ